QQ客服 官方微博 反馈留言

	Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.
	Gadgeel, Shirish M.; Dols, Manuel Cobo; Felip, Enriqueta; Soria, Jean-Charles; Lee, Ki Hyeong; Lu, Shun; Georgoulias, Vassilis; Fulop, Andrea; Goker, Erdem; Syrigos, Konstantinos N.
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2015
卷号	33期号:15
ISSN号	0732-183X
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3544266
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Gadgeel, Shirish M.,Dols, Manuel Cobo,Felip, Enriqueta,et al. Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.[J]. JOURNAL OF CLINICAL ONCOLOGY,2015,33(15).
APA	Gadgeel, Shirish M..,Dols, Manuel Cobo.,Felip, Enriqueta.,Soria, Jean-Charles.,Lee, Ki Hyeong.,...&Goss, Glenwood D..(2015).Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial..JOURNAL OF CLINICAL ONCOLOGY,33(15).
MLA	Gadgeel, Shirish M.,et al."Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.".JOURNAL OF CLINICAL ONCOLOGY 33.15(2015).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。